INTRODUCTION

Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism, is a common life-threatening illness with significant morbidity and mortality rates. VTE is a growing worldwide health concern with an annual incidence of 104 to 183 events per 100,000 individuals in the Caucasian population [1,2]. In Korea, a 2008 survey reported that the annual incidence of VTE per 100,000 individuals was 13.8, which represented an increase from the results of a 2004 survey [3]. This study was designed to understand the current trends in the management of acute DVT in Korea.

MATERIALS AND METHODS

A 20-item questionnaire was prepared and sent to 48 members of the Korean Society for Vascular Surgery. The members worked in 48 different hospitals. Twenty-two members completed and returned the questionnaire.
results

The vascular surgery departments (91%) were primarily responsible for managing VTEs, followed by the cardiology departments (Fig. 1). Initial diagnostic tools for DVT were ultrasound (73%), computed tomography (CT) venography (77%), D-dimer tests (64%), and conventional venography (5%) (Fig. 2). The coagulation factor assay was routinely performed in 82% of hospitals.

1) Thrombolysis

The procedure of thrombolysis, including mechanical thrombectomy, was mainly performed in the radiology departments (59%), followed by the vascular surgery departments (23%). When queried about age limitations for thrombolysis, 45% of respondents stated that there was no limitation, 9% felt that thrombolysis should be restricted to patients under 65 years of age, and 46% felt that thrombolysis should be restricted to patients under 70 years of age. When queried about limitations in time after onset of thrombi, answers of 7 days, 14 days, 21 days, and more than 28 days were made by 9%, 36%, 32%, and 23% of respondents, respectively. The durations of thrombolysis of up to 1 day and up to 2 days were preferred by 45% and 23% of respondents, respectively.

In addition, 45% of respondents did not have experience with open thrombectomy, 18% had experience with 1-5 cases of open thrombectomy, and 37% had experience with more than 5 cases of open thrombectomy. The reported indications of open thrombectomy included phlegmasia alba dolens, phlegmasia cerulea dolens, patients who were not indicated for anticoagulation therapy, and the presence of tumor thrombi.

2) Inferior vena cava filter insertion

Inferior vena cava (IVC) filter insertions were mainly performed in the radiology departments (55%), followed by the vascular surgery & cardiology (90%).

![Fig. 1. Proportion of departments in charge of deep vein thrombosis treatment.](chart1.png)

![Fig. 2. Initial diagnostic tools in deep vein thrombosis. CT, computed tomography.](chart2.png)

![Fig. 3. Anticoagulation therapy (A) where treated, (B) on admission, what heparin used. UFH, unfractionated heparin; LMWH, low molecular weight heparin.](chart3.png)
vascular surgery departments. Fifty percent of respondents routinely inserted IVC filters, and 45% of respondents selectively inserted IVC filters. The indications for selective IVC filter insertion were the following: high risk for pulmonary embolism and floating IVC or iliac vein thrombi. Temporary IVC filters that were inserted after thrombolysis were removed after 2 weeks (41%), 1 week (18%), and 4 weeks (18%).

3) Anticoagulation therapy

Eighty-two percent of respondents treated acute DVT patients upon admission to the clinic, and 18% treated patients on an outpatient basis. On admission, 73% of respondents used low-molecular weight heparin, and 22% used unfractionated heparin (Fig. 3). Fifty percent of respondents used the newly developed oral anticoagulation agent rather than warfarin. With regard to oral anticoagulation, the majority of respondents (77%) used oral anticoagulation therapy over a >12-month period when the patient had abnormal anticoagulation factors. If there was no abnormality in the anticoagulation factor assay, the majority of respondents used oral anticoagulation therapy for 6 months (76%). Overlap of heparin and warfarin was carried out by 50% of respondents on day 1 (13%), day 2 (13%), day 3 (18%), and day 7 (5%) (Fig. 4). Sixty-eight percent of respondents maintained the optimal therapeutic international normalized range at 2-3, and 32% of respondents maintained it at 1.5-2. Beyond the first few days, warfarin was preferred over rivaroxaban (Bayer, Leverkusen, Land Nordrhein-Westfalen, Germany). The length of treatment with anticoagulants was 3 months for surgery-triggered DVT, rather than 6 or 12 months. For DVTs that were caused by non-surgical risk factors, such as estrogen therapy, long-distance travel, and non-surgical hospitalizations, the length of treatment was 3 months, rather than 6 months, 12 months, or longer. Finally, for unprovoked (idiopathic) DVT, long-term treatment was recommended if the risk for bleeding was low [4].

The incidence of VTE in the Asian population has generally been lower than that among Caucasian populations, although it appears to be gradually increasing [5,6]. Regardless of the clinical significance of VTE, a nationwide epidemiologic study has never been performed in the Asian population. The 2012 ACCP guidelines were chiefly based on data from the Caucasian population and have provided useful information about VTE for physicians. However, the incidence and risk factors of VTE are clearly different between Caucasian and Asian populations. Genetic mutations have been suggested as an explanation for significant differences between Asians and Caucasians.

DISCUSSION

In 2012, the American College of Chest Physicians (ACCP) revised the eighth edition of evidence-based clinical practice guidelines for VTE. Specifically, they recommended using anticoagulants to treat proximal DVT. Thrombolytics or clot extraction interventions (thrombectomy) were not recommended for routine use. Patients who were most likely to benefit from catheter-directed thrombolysis (CDT) were those having iliofemoral DVT, symptoms within 14 days, good functional status, and a low risk of bleeding. The ACCP guidelines recommended outpatient treatment. In the acute setting (i.e., the first few days, according to the guidelines), the recommendation was to use dalteparin (Fragmin; Pfizer, New York, NY, USA), tinzaparin (Innohep; Leo Pharma Inc., Ballerup, Denmark), or fondaparinux (Arixtra; GlaxoSmithKline, London, England) once daily. Alternatively, enoxaparin (Lovenox; Sanofi-Aventis, Paris, France) may be used twice daily. Beyond the first few days, warfarin was preferred over rivaroxaban (Bayer, Leverkusen, Land Nordrhein-Westfalen, Germany). The length of treatment with anticoagulants was 3 months for surgery-triggered DVT, rather than 6 or 12 months. For DVTs that were caused by non-surgical risk factors, such as estrogen therapy, long-distance travel, and non-surgical hospitalizations, the length of treatment was 3 months, rather than 6 months, 12 months, or longer. Finally, for unprovoked (idiopathic) DVT, long-term treatment was recommended if the risk for bleeding was low [4].

The incidence of VTE in the Asian population has generally been lower than that among Caucasian populations, although it appears to be gradually increasing [5,6]. Regardless of the clinical significance of VTE, a nationwide epidemiologic study has never been performed in the Asian population. The 2012 ACCP guidelines were chiefly based on data from the Caucasian population and have provided useful information about VTE for physicians. However, the incidence and risk factors of VTE are clearly different between Caucasian and Asian populations. Genetic mutations have been suggested as an explanation for significant differences between Asians and Caucasians. Previous studies reported an incidence of hereditary thrombophilia of approximately 15%-30% in Caucasians. Genetic mutations, particularly those for clotting factor V (factor V Leiden) and factor II G20210A, are highly prevalent in Caucasians but are absent in Asians [7-9]. Individuals with one of these genetic mutations have a 3-4-fold higher risk of developing VTE [10,11]. Another possible cause of VTE is lifestyle. Little was known about the role of lifestyle in the development of VTE until recently, and dietary intake has been suggested as a changeable risk factor for the
Kim and Kim

development of VTE. A prospective cohort study suggested that the intake of more fish and plant-based foods with less red meat was associated with a lower incidence of VTE [12]. For this reason, an epidemiologic study may help us understand its incidence and pathophysiology. The present findings may allow one to properly apply the ACCP guidelines to DVT patients in Korea.

Although the majority of Korean vascular surgeons followed the ACCP guidelines, local availability and access to testing may preclude one’s ability to follow these guidelines. For diagnosis, one of the following initial tests is recommended: a moderately sensitive D-dimer test, a highly sensitive D-dimer test, or a compression ultrasound of the proximal veins in patients with suspected first lower-extremity DVT. Our findings show that the ultrasound (73%), CT venography (77%), and the D-dimer (64%) test were all used in Korea. The ACCP guidelines recommend CT scans only if the other tests are not possible. However, CT scans for DVT were excessively used by the respondents in the study. This study has several limitations. First, the survey was only performed on vascular surgeons. Therefore, it was difficult to determine the general trend for DVT treatment in Korea. Second, the ACCP guidelines list specific points regarding anticoagulation therapy in patients during perioperative and postoperative periods. Intensive care unit patients, as well as those with cardiovascular disease or orthopedic issues, may tolerate anticoagulation therapy in different manners. Because communication was not properly carried out between the surveyor and respondents, DVT-related data on all types of patients were included in this survey.

CONCLUSION

This survey provided a greater understanding of both treatment procedures for DVT and compliance with ACCP guidelines. The majority of Korean vascular surgeons followed the ACCP guidelines. However, CT scans were performed more frequently than recommended. Also, thrombolysis and IVC filter insertions were used more often, due to insurance, accessibility, and lower fees. Although the admittance and treatment of DVT patients is generally considered to be convenient and safe, it is important to choose proper diagnostic procedures and treatment plans that will comply with the ACCP guidelines.

ACKNOWLEDGEMENTS

This study was designed to report in the 2014 Korea-Japan Joint Meeting of Vascular Surgery on April 2013.

We thank Dr. Jungnam Kwon (Wonkwang University), Yongshin Kim (Sungkyunkwan University), Hyongtae Kim (Keimyung University), Seungkee Min (Seoul National University), Kihyuk Park (Catholic University of Daegu), Jehoon Park (Inje University), Jongkwon Park (Inje University), Byungjun So (Wonkwang University), Moonsang Ahn (Chungnam National University), Sangsoo Yun (The Catholic University of Korea), Ikjin Yun (Konkuk University), Sangsu Lee (Pusan National University), Sunjung Lee (Sungkyunkwan University), Seoung Huh (Kyungpook National University), Keechun Hong (Inha University), and Heechul Yu (Chonbuk National University) for their participation in this survey.

REFERENCES

1) Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007;5:692-699.
2) Oger E, Mottier D. Incidence and risk factors for venous thromboembolism. Rev Prat 2007;57:711-3, 716, 719-720.
3) Jang MJ, Bang SM, Oh D. Incidence of venous thromboembolism in Korea: from the Health Insurance Review and Assessment Service database. J Thromb Haemost 2011;9:85-91.
4) Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounaumeaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e419S-e494S.
5) Kobayashi T, Nakamura M, Sakuma M, Yamada N, Sakon M, Fujita S, et al. Incidence of pulmonary thromboembolism (PTE) and new guidelines for PTE prophylaxis in Japan. Clin Hemorheol Microcirc 2006;35:257-259.
6) Lee LH, Gu KQ, Heng D. Deep vein thrombosis is not rare in Asia--the Singapore General Hospital experience. Ann Acad Med Singapore 2002;31:761-764.
7) Ro A, Hara M, Takada A. The factor V
Leiden mutation and the prothrombin G20210A mutation was not found in Japanese patients with pulmonary thromboembolism. Thromb Haemost 1999;82:1769.

8) Shen MC, Lin JS, Tsay W. Factor V Arg306 → Gly mutation is not associated with activated protein C resistance and is rare in Taiwanese Chinese. Thromb Haemost 2001;85:270-273.

9) Song KS, Park YS, Kim HK, Choi JR, Park Q. Prevalence of Arg306 mutation of the factor V gene in Korean patients with thrombosis. Haemostasis 1998;28:276.

10) Huh SH, Kim DI, Kim ES, Lee BB, Moon JY, Joh JH. Clinical and functional assessment after anticoagulant therapy of acute deep vein thrombosis involving the lower limb. Yonsei Med J 2003;44:686-693.

11) Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 2005;293:2352-2361.

12) Steffen LM, Folsom AR, Cushman M, Jacobs DR Jr, Rosamond WD. Greater fish, fruit, and vegetable intakes are related to lower incidence of venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology. Circulation 2007;115:188-195.